
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
VITAL™ VIDEO SERIES
|
MEET THE FACULTY
|
RESOURCES AND LINKS
© Janssen Pharmaceuticals, Inc. 2011. All rights reserved.




